Not Just Drug Demand $Eli Lilly(LLY)$’s August 5 report arrives with little doubt that demand for its diabetes and obesity medicines is strong. The harder question is whether production, pricing and access can turn that demand into sustainable earnings at a valuation that already anticipates exceptional growth. Lilly reported its first quarter on April 30. Revenue increased 56% year over year to $19.8 billion, primarily because of higher Mounjaro and Zepbound volume, partly offset by lower realised prices. Key-product revenue reached $13.4 billion, and reported earnings increased 170% to $8.26 per share. Mounjaro and Zepbound together represented 65% of quarterly revenue, demonstrating both extraordinary momentum and material concentration. Lilly’s

$Vertiv Holdings LLC(VRT)$ reported objectively strong second-quarter results on July 29, 2026. Revenue, margins, earnings and cash flow all rose sharply, and management increased its full-year guidance. Yet the shares initially sold off because quarterly revenue fell short of the market’s elevated expectations. The reaction illustrates a new phase for AI infrastructure stocks: rapid growth is no longer sufficient when valuations already assume nearly flawless execution. Second-quarter net sales increased 24% to $3.274 billion, including organic growth of 18%. Operating profit rose 44%, while adjusted operating profit increased 51%. Adjusted operating margin expanded by 410 basis points to 22.6%, and adjusted diluted earnings per share increased 60

$Boeing(BA)$’s second-quarter performance marked another step away from crisis management and toward operational recovery. The company’s shares rose on July 28, 2026, after its results showed positive free cash flow and improving aircraft deliveries. For investors, the essential question is no longer whether Boeing has demand. Its commercial backlog already demonstrates that. The real question is whether Boeing can convert that demand into aircraft, cash and sustainable margins without triggering another quality setback. Boeing announced its second-quarter results on July 28, following the earlier release of its quarterly delivery data on July 14. Boeing’s official second-quarter delivery announcement and its investor materials provide the relevant

$Intel(INTC)$’s second-quarter results demonstrated a meaningful operating recovery: revenue accelerated, gross margin improved and data-centre sales surged. However, the company is committing more capital to manufacturing before its foundry business has conclusively demonstrated that it can generate acceptable returns. Intel reported the results after the market closed on July 23 for the quarter ended June 27. Revenue increased 25% to $16.1 billion, representing the company’s strongest growth in more than 15 years. Non-GAAP earnings reached $0.42 per share, while operating cash flow improved to $7 billion. Intel’s official second-quarter release provides the results. The segment figures were encouraging. Client Computing

$Cxmt Corporation(688825)$’s 466% Shanghai debut transformed a Chinese semiconductor company into an immediate stock-market giant. More importantly for US investors, the listing gives China’s largest domestic DRAM producer billions of dollars to expand capacity and challenge Micron, Samsung and SK Hynix. CXMT sold shares at 8.66 yuan and closed its July 27 debut at 49 yuan after reaching 55.03 yuan. The company raised 57.92 billion yuan, or approximately $8.6 billion, while its market capitalization reached roughly $488 billion. Only 6.73% of the enlarged share count was freely tradable, which likely amplified the price increase. Reuters’ report on CXMT’s trading debut provides the offering and float data. CXMT manufactures DRAM used in smartpho